-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31

Benzinga·07/07/2026 12:30:08
Listen to the news
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $28 to $31.